An Open-label, Randomized, Parallel Group, Single Dose Study to Investigate the PK and Safety of Belimumab 200 mg Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Participants

This is an open-label, randomized, parallel group, single dose study in healthy Chinese
subjects. The purpose of this study is to characterize the pharmacokinetic profile and safety
profile of 200 mg single dose of belimumab, administered either intravenously or
subcutaneously via auto-injector. Each subject will be randomized in a 1:2 ratio to receive a
single dose of either intravenous (IV) or subcutaneous (SC) administration of belimumab 200
mg. The total study duration will be approximately 13 weeks.